Zavamet 1000 Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. This dual mechanism of action effectively improves glycemic control by targeting both fasting and postprandial blood glucose levels. Zavamet 1000 Tablet is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. The combination therapy offers the advantage of complementary pharmacodynamics, potentially reducing the risk of hypoglycemia and minimizing adverse effects associated with higher doses of individual agents. Patients should be monitored regularly for renal function, hepatic function, and glycemic parameters during treatment. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to any component. Zavamet 1000 Tablet should be used under medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes in type 2 diabetes management.